Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LRMR OTCMKTS:SEOVF NASDAQ:TLSA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLRMRLarimar Therapeutics$3.68+0.5%$3.87$2.55▼$6.42$380.21M0.831.82 million shs1.98 million shsSEOVFSernova Biotherapeutics$0.11-10.2%$0.12$0.09▼$0.16$44.56M0.8231,589 shs55,175 shsTLSATiziana Life Sciences$1.16+0.9%$1.32$1.04▼$2.60$146.35M0.44219,808 shs59,549 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLRMRLarimar Therapeutics+0.55%+8.24%+6.67%-21.37%+52.07%SEOVFSernova Biotherapeutics-10.17%+0.47%-2.57%-13.68%-12.03%TLSATiziana Life Sciences+0.87%+5.45%-21.62%-14.07%-25.16%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLRMRLarimar Therapeutics$3.68+0.5%$3.87$2.55▼$6.42$380.21M0.831.82 million shs1.98 million shsSEOVFSernova Biotherapeutics$0.11-10.2%$0.12$0.09▼$0.16$44.56M0.8231,589 shs55,175 shsTLSATiziana Life Sciences$1.16+0.9%$1.32$1.04▼$2.60$146.35M0.44219,808 shs59,549 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLRMRLarimar Therapeutics+0.55%+8.24%+6.67%-21.37%+52.07%SEOVFSernova Biotherapeutics-10.17%+0.47%-2.57%-13.68%-12.03%TLSATiziana Life Sciences+0.87%+5.45%-21.62%-14.07%-25.16%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLRMRLarimar Therapeutics 3.10Buy$13.50266.85% UpsideSEOVFSernova Biotherapeutics 0.00N/AN/AN/ATLSATiziana Life Sciences 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest TLSA, LRMR, and SEOVF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2026TLSATiziana Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/27/2026LRMRLarimar Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$9.005/18/2026LRMRLarimar Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$13.00 ➝ $12.005/6/2026TLSATiziana Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026LRMRLarimar Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/25/2026LRMRLarimar Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 6/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLRMRLarimar TherapeuticsN/AN/AN/AN/A$0.94 per shareN/ASEOVFSernova BiotherapeuticsN/AN/AN/AN/A($0.05) per shareN/ATLSATiziana Life SciencesN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLRMRLarimar Therapeutics-$165.67M-$2.06N/AN/AN/AN/A-134.14%-96.00%8/13/2026 (Estimated)SEOVFSernova Biotherapeutics-$11.24M-$0.04N/AN/AN/AN/AN/A-1,327.02%9/10/2026 (Estimated)TLSATiziana Life Sciences-$18.43MN/AN/AN/AN/AN/AN/AN/AN/ALatest TLSA, LRMR, and SEOVF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/11/2026Q2 2026SEOVFSernova Biotherapeutics-$0.0074-$0.01-$0.0026-$0.01N/AN/A5/14/2026Q1 2026LRMRLarimar Therapeutics-$0.53-$0.31+$0.22-$0.31N/AN/A5/1/2026Q4 2025TLSATiziana Life SciencesN/A-$0.2750N/A-$0.2750N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthLRMRLarimar TherapeuticsN/AN/AN/AN/AN/ASEOVFSernova BiotherapeuticsN/AN/AN/AN/AN/ATLSATiziana Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLRMRLarimar TherapeuticsN/A4.294.29SEOVFSernova BiotherapeuticsN/A0.030.03TLSATiziana Life SciencesN/A0.760.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLRMRLarimar Therapeutics91.92%SEOVFSernova BiotherapeuticsN/ATLSATiziana Life SciencesN/AInsider OwnershipCompanyInsider OwnershipLRMRLarimar Therapeutics4.50%SEOVFSernova BiotherapeuticsN/ATLSATiziana Life Sciences39.82%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLRMRLarimar Therapeutics30103.88 million99.21 millionOptionableSEOVFSernova BiotherapeuticsN/A377.64 millionN/ANot OptionableTLSATiziana Life Sciences8127.26 million76.58 millionOptionableTLSA, LRMR, and SEOVF HeadlinesRecent News About These CompaniesWhy Tiziana Life Sciences Is Back on the Small-Cap Radar?June 19, 2026 | kalkinemedia.comKTiziana Life Sciences Announces Purchase of Shares by Executive ChairmanJune 15, 2026 | globenewswire.comTiziana Life Sciences Ltd.: Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New YorkMay 29, 2026 | finanznachrichten.deTiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New YorkMay 28, 2026 | globenewswire.comTiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data – ICYMIMay 22, 2026 | proactiveinvestors.comTiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data – ICYMIMay 22, 2026 | proactiveinvestors.comTiziana Life Sciences Stock Rises Over 9% After Multiple Sclerosis Trial Enrollment UpdateMay 21, 2026 | finance.yahoo.comTiziana Life Sciences completes enrollment in Phase 2a multiple sclerosis trialMay 21, 2026 | proactiveinvestors.comTiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis TrialMay 21, 2026 | globenewswire.comTiziana Life Sciences price target boosted on foralumab updateMay 19, 2026 | proactiveinvestors.comTiziana says updated data for multiple sclerosis therapy shows long-term safetyMay 19, 2026 | seekingalpha.comTiziana Life Sciences reports encouraging one-year data for intranasal foralumab in progressive MSMay 19, 2026 | proactiveinvestors.comTiziana Life Sciences Ltd.: Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple SclerosisMay 19, 2026 | finanznachrichten.deTiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple SclerosisMay 19, 2026 | globenewswire.comTiziana Brain Trial Draws Fresh Nasdaq Index AttentionMay 16, 2026 | kalkinemedia.comKTiziana Life Sciences reports brain inflammation reductions in Multiple System Atrophy trialMay 14, 2026 | proactiveinvestors.comTiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal ForalumabMay 14, 2026 | globenewswire.comTiziana Life Sciences Delays Annual 20-F FilingMay 2, 2026 | theglobeandmail.comTiziana Life Sciences Ltd.: Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and ...April 17, 2026 | finanznachrichten.deTiziana says intranasal drug shows potential to ease Long COVID “brain fog”April 16, 2026 | proactiveinvestors.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTLSA, LRMR, and SEOVF Company DescriptionsLarimar Therapeutics NASDAQ:LRMR$3.68 +0.02 (+0.55%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$3.68 0.00 (0.00%) As of 06/23/2026 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.Sernova Biotherapeutics OTCMKTS:SEOVF$0.11 -0.01 (-10.17%) As of 06/23/2026 03:17 PM EasternSernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs. Sernova Corp. has a research agreement with the University of Miami to advance the development of Conformal Coating Technology in combination with therapeutic cells within Cell Pouch. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada.Tiziana Life Sciences NASDAQ:TLSA$1.16 +0.01 (+0.87%) As of 06/23/2026 04:00 PM EasternTiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning These AI Stocks Have Insider Selling, But Buyers Still Have a Reason to Stay Apple’s Intel Deal Arrives at the Right Time for Its Stock Micron’s Sudden Plunge May Be an AI Buying Chance Amazon’s Pullback Deepens as a New FTC Risk Hits the Stock The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. How Does D-Wave's New Simulator Change the Quantum Computing Landscape? How Intel Is Packaging the Future of American Chips Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
